Table 2 Distribution of the study population by age group, gender, maintenance therapy and strength of therapy
From: Pitfalls associated with the therapeutic reference pricing practice of asthma medication
High dose therapy | Medium dose therapy | |||||||
|---|---|---|---|---|---|---|---|---|
Male | Female | Male | Female | |||||
Age group (year) | Seretide | Symbicort | Seretide | Symbicort | Seretide | Symbicort | Seretide | Symbicort |
18-30 | 93 (3.7%) | 125 (7.6%) | 100 (3.0%) | 79 (3.5%) | 364 (16.4%) | 728 (16.5%) | 321 (7.7%) | 703 (9.7%) |
31-40 | 176 (7.0%) | 188 (11.4%) | 195 (5.8%) | 183 (8.2%) | 295 (13.3%) | 753 (17.1%) | 355 (8.5%) | 804 (11.1%) |
41-50 | 249 (9.9%) | 210 (12.8%) | 424 (12.6%) | 336 (15.0%) | 305 (13.8%) | 627 (14.2%) | 556 (13.3%) | 1 106 (15.3%) |
51-60 | 654 (26.1%) | 382 (23.2%) | 1 008 (30.0%) | 685 (30.6%) | 451 (20.3%) | 878 (19.9%) | 1 100 (26.4%) | 1 956 (27.0%) |
61-70 | 679 (27.1%) | 416 (25.3%) | 842 (25.0%) | 522 (23.3%) | 423 (19.1%) | 797 (18.1%) | 954 (22.9%) | 1 528 (21.1%) |
71-X | 654 (26.1%) | 326 (19.8%) | 795 (23.6%) | 436 (19.5%) | 380 (17.1%) | 622 (14.1%) | 887 (21.3%) | 1 149 (15.9%) |
Total | 2 505 (100%) | 1 647 (100%) | 3 364 (100%) | 2 241 (100%) | 2 218 (100%) | 4 405 (100%) | 4 173 (100%) | 7 246 (100%) |